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Objective: To describe and synthesize the current stereotactic radiosurgery (SRS) and
stereotactic body radiation therapy (SBRT) cost-effectiveness research to date across sev-
eral common SRS and SBRT applications.
Methods: This review was limited to comparative economic evaluations of SRS, SBRT,
and alternative treatments (e.g., other radiotherapy techniques or surgery). Based on
PubMed searches using the terms, “stereotactic,” “SRS,” “stereotactic radiotherapy,”
“stereotactic body radiotherapy,” “SBRT,” “stereotactic ablative radiotherapy,” “economic
evaluation,” “quality adjusted life year (QALY),” “cost,” “cost-effectiveness,” “cost-utility,”
and “cost analysis,” published studies of cost-effectiveness and health economics were
obtained. Included were articles in peer-reviewed journals that presented a comparison of
costs between treatment alternatives from January 1997 to November 2012. Papers were
excluded if they did not present cost calculations, therapeutic cost comparisons, or health
economic endpoints.
Results: Clinical outcomes and costs of SRS and SBRT were compared to other therapies
for treatment of cancer in the brain, spine, lung, prostate, and pancreas. Treatment out-
comes for SRS and SBRT are usually superior or comparable, and cost-effective, relative
to alternative techniques.
Conclusion: Based on the review of current SRS and SBRT clinical and health economic
literature, from a patient perspective, SRS and SBRT provide patients a clinically effec-
tive treatment option, while from the payer and provider perspective, SRS and SBRT
demonstrate cost savings.
Keywords: cost-effectiveness, health economics, stereotactic body radiotherapy, stereotactic body radiation
therapy, stereotactic radiosurgery, cancer
INTRODUCTION
For over 40 years clinicians have treated intracraniallesions with
stereotactic radiosurgery (SRS). In the beginning, this non-
invasive, highly innovative technique was received with great
skepticism by the leaders of academic neurosurgery and radi-
ation oncology. After 20 years of successful use in Sweden, the
first Gamma Knife treatment was performed in North America in
1987 at the University of Pittsburgh. In 1989, the Gamma Knife
was first used to treat the most common brain pathology, brain
metastases (Lindquist, 1989). Since that time, radiosurgery has
been shown to have excellent clinical outcomes and to be a cost-
effective treatment option for patients with brain metastases (Lee
et al., 2009).
Starting in 1995, Blomgren et al. (1995) and Hamilton et al.
(1995) provided the first results of radiosurgical techniques out-
side of brain and spine in a procedure that has come to be called
stereotactic body radiation therapy (SBRT). SBRT is the image-
guided delivery of high dose radiation in an extremely hypofrac-
tionated treatment (typically up to five fractions). Delivering such
high doses per fraction requires high conformality and steep dose
fall-off to avoid irradiating organs at risk; this necessitates image-
guidance for patient setup and, preferably, throughout treatment
to adjust for changes in tumor/target position, thus minimiz-
ing treatment-related toxicity. Advances in image-guidance have
allowed clinicians to safely deliver both SRS and SBRT, and as the
growing body of literature has supported the safety and efficacy of
these procedures, their utilization has steadily increased.
Before the advent of frameless techniques, Gamma Knife was
primarily used to deliver SRS. Although it is an effective radio-
surgery device, it is limited to treating only intracranial and upper
spinal lesions due to the necessity of a rigid head frame. The
frame also effectively limits the Gamma Knife to single-session
(or fraction) treatment. For intracranial lesions, fractionated SRS
may provide additional normal tissue protection when treating
tumors near functional regions such as the optic chiasm or inner
ear (Chang et al., 2005; Adler et al., 2006). The CyberKnife was
built on the principles of Gamma Knife radiosurgery, delivering
both isocentric treatments (like Gamma Knife) and non-isocentric
treatments, but does not require a rigid head frame. Instead fre-
quent image-guidance is used to locate the target (in some cases
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based on the position of implanted fiducial markers) and adjust the
beam aim should any changes in target position be detected. The
CyberKnife is also able to track and automatically correct for respi-
ratory motion of targets in lung, liver, pancreas, etc. Although the
CyberKnife was designed specifically for SRS/SBRT, SBRT, and SRS
can also be delivered by gantry-based radiotherapy systems (e.g.,
Varian Truebeam, BrainLab’s Novalis TX, or BrainLab/Mitsubishi
Vero). These systems also employ image-guidance for patient setup
and, in some cases, occasional intra-fraction verification of target
position, in addition to some combination of patient and target
restraint using body frames and abdominal compression devices,
breathing control, or respiratory gating to manage respiratory
motion, and implanted fiducials or electromagnetic beacons.
As SRS and SBRT have grown, so has the clinical literature
describing its application in treating a variety of tumors and lesions
throughout the body including those in the brain, head/neck,
spine, lung, liver, prostate, and pancreas. Despite the growing body
of clinical SRS and SBRT literature, there is limited research into
the cost-effectiveness and health economic outcomes of these pro-
cedures. Our long-term goal is to develop valid health economic
research on SBRT and SRS; the current paper aims to describe and
synthesize the SRS and SBRT cost-effectiveness research to date
for several common SRS/SBRT indications.
METHODS
SEARCH STRATEGY
Based on a PubMed search using the terms, “stereotactic,”
“SRS,” “stereotactic radiotherapy,” “stereotactic body radiother-
apy,” “SBRT,” “stereotactic ablative radiotherapy,” “economic
evaluation,” “quality adjusted life year (QALY),” “cost,” “cost-
effectiveness,” “cost-utility,” and “cost analysis,” published studies
of cost-effectiveness and health economics were obtained. Inclu-
sion criteria were limited to articles in published peer-reviewed
journals and needed to include a comparison of costs between
alternatives from January 1997 to November 2012.
INCLUSION/EXCLUSION CRITERIA
This review includes only comparative studies of SRS, SBRT, and
alternative treatments in economic evaluations. Inclusion crite-
ria were limited to articles in published peer-reviewed journals
and needed to include a comparison of costs between alternatives
from January 1997 to November 2012. Exclusion criteria included
the absence of cost calculations, therapeutic cost comparisons,
and health economic endpoints. Title, abstracts and full-text arti-
cles of all identified studies were reviewed independently by two
co-authors.
BRAIN
There are several published cost-effectiveness studies that focus
on the clinical efficacy and cost-effectiveness of SRS compared to
surgery (Table 1). One of the main reasons for this is that patients
are treated with SRS on an outpatient basis compared with surgery,
which requires utilization of inpatient hospital resources. Vuong
et al. (2013) found that the average cost in Germany per patient
for surgical resection was C11,647 compared to C9,964 for SRS. In
addition, the survival time for surgical resection was 13.0 months
while the survival time for SRS was 18.4 months. Also in Germany,
Wellis et al. (2003) calculated the treatment costs of SRS and micro-
surgery for the treatment of meningiomas, acoustic neuromas,
metastases, and arteriovenous malformations. For microsurgery,
the average hospitalization time was 15.4± 8.6 days with 1.2± 2.8
of those days spent in the intensive care unit (ICU). The total aver-
age costs of microsurgery per patient including ancillary therapy
and unplanned readmissions was C15,252, while the total aver-
age cost of SRS per patient was C7,920. Along the same lines, in
Netherlands, van Roijen et al. (1997) analyzed costs and effects
of treating acoustic neuroma patients with either microsurgery
or radiosurgery. Direct costs for microsurgery were Dfl. 20,072
and Dfl. 14,272 for radiosurgery, while indirect costs were Dfl.
16,400 for microsurgery and Dfl. 1,020 for radiosurgery. In addi-
tion, the general health rating was better for radiosurgery than
for microsurgery. Banerjee et al. (2008) also compared the costs
of microsurgery to radiosurgery for the treatment of vestibular
schwannoma. For microsurgery patients who were followed up
for at least 36 months, mean surgical costs were $23,788, while
for radiosurgery patients, the mean surgical costs were $16,143.
For microsurgery patients, the mean follow-up costs per month
started at over $1,000 per month and decreased steadily to less than
$70 per month by the tenth month of follow-up. The mean follow-
up costs for patients in the radiosurgery group were less than
$10 per month for the first few months and thereafter increased
to as much as $200 per month. In addition, the microsurgery
patients suffered a significant decline from pre-operative levels in
several components of the health status questionnaire (HSQ) at
3 months, 1 year, and most-recent follow-up; however, the radio-
surgery group showed no decline in HSQ across all follow-up time
frames.
Manning et al. (2000) compared the treatment cost of linac-
based hypofractionated stereotactic radiotherapy (HSRT) and SRS
for the treatment of brain metastases. The median absolute cost
of SRS was $4,119 higher than HSRT. In Taiwan, Cho et al. (2006)
compared the direct and indirect costs from both hospital and
societal perspectives for SRS and open surgery for the treatment
of benign cranial base tumors. For open surgery, the mean length
of stay was 18.2± 30.4 days including 5.0± 14.7 days of ICU stay
and 13.0± 15.2 days of ward stay. The mean hospital stay for SRS
was 2.2± 0.9 days with no need of ICU stay. The mean loss of
workdays for open surgery was 160± 158 and 8.0± 9.0 days for
SRS. The direct cost for SRS was higher than that for open surgery
($9,677± $6,700 vs. $5,837± 6,587). Open surgery had a higher
complication rate (31.2%) compared to SRS (3.8%). Open surgery
had a mortality rate of 5.3% while there was no mortality for
SRS. The socioeconomic costs were significantly higher for open
surgery compared to SRS ($34,453± 97,277 vs. $10,044± 7,481).
Finally, the cost per QALY was significantly lower with SRS com-
pared to open surgery ($3,762/QALY vs. $8,996/QALY). Along the
same lines, Tarricone et al. (2008) compared the full treatment
costs of SRS vs. microvascular decompression (MVD) for trigem-
inal neuralgia. The MVD full treatment costs were C6,641 per
patient while the full SRS treatment costs were C4,388 per patient.
The difference was attributed to the cost of the surgical proce-
dure and the cost of inpatient hospitalization for MVD, which
was, on average, 10 days (no hospitalization is required for SRS).
Lal et al. (2012) utilized a decision analysis model to compare
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SRS plus observation vs. SRS plus whole-brain radiation ther-
apy (WBRT). The median survival of the SRS plus observation
group was 15.2 months, while the median survival for SRS plus
WBRT was 5.7 months. However, the recurrence rates were higher
for patients treated with SRS plus observation compared to SRS
plus WBRT (71 vs. 15%). Compared with SRS plus WBRT, SRS
plus observation had a higher average cost ($74,000 vs. $119,000)
but a higher average effectiveness [0.60 life years saved (LYS)
vs. 1.64, respectively] with an incremental cost-effectiveness ratio
(ICER) of $44,231 per LYS or $41,783 per QALY (10-year hori-
zon). Rutigliano et al. (1995) developed a cost-effectiveness model
that compared the results of surgical resection and SRS for the
treatment of solitary metastatic brain tumors. The study found
that SRS had a lower uncomplicated procedure cost ($20,209 vs.
$27,587), a lower average complication cost per case ($2,534 vs.
$2,874), a lower total cost per procedure ($22,743 vs. $30,461), was
more cost-effective ($24,811 vs. $32,149 per life year) and had a
better incremental cost-effectiveness ($40,648 vs. $52,384 per life
year) compared to surgical resection. Treatment-related morbid-
ity and mortality were higher with surgical resection compared to
radiosurgery (29.7 vs. 12.9%; 6.6 vs. 0%). Tan et al. (2011) com-
pared the initial and post-treatment (1-year) costs of microsurgery,
linac radiosurgery, and Gamma Knife radiosurgery in menin-
gioma patients. Initial treatment costs were C12,299, C1,547, and
C2,412 for microsurgery, linac radiosurgery, and Gamma Knife
radiosurgery respectively. Microsurgery patients were admitted
for an average of 11.3 inpatient days, which contributed to the
higher microsurgery costs. Microsurgery inpatient stay cost was
C5,321 while the indirect cost was C4,350. The microsurgery
inpatient cost was nearly 14 times higher than linac or Gamma
Knife radiosurgery (C5,321 vs. C386). In addition, the 1-year
follow-up costs were C2,041 for microsurgery, C1,514 for linac
radiosurgery, and C1,553 for Gamma Knife. This accounted for
both treatment-related and treatment-unrelated costs. The annual
total costs, including equipment cost per fraction, were C14,329
for microsurgery, C3,060 for linac radiosurgery, and C3,966 for
Gamma Knife. Mehta et al. (1997) compared the outcomes of
treatment with a combination therapy of radiation therapy (RT)
plus surgery or RT plus radiosurgery. The median cost for RT
plus surgery was $22,018 while the cost median costs of RT plus
radiosurgery was $15,102, while the cost-effectiveness was signifi-
cantly better for RT plus radiosurgery compared to RT plus surgery
($13,729 vs. $27,523 per year of survival gained). The average cost
of QALY was $15,012 for RT plus radiosurgery, $31,454 per QALY
for RT plus surgery, and $32,500 per QALY for RT alone.
Some of the limitations of these studies include the lack of
direct clinical and health economic comparison between treat-
ment options, resource cost utilization unrelated to treatment, as
well as lack of following patient quality of life outcomes. Future
cost-effectiveness study design should consider direct clinical and
health economic comparisons between treatment options as well
as capturing the follow-up costs related directly to treatment, and
the cost of lost work-time and reduced efficiency. Although these
studies reviewed do have some limitations, they are extremely valu-
able in demonstrating that as hospitals and health systems look to
provide high-quality, cost-effective treatment options, compared
to surgery, SRS is an attractive alternative.
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SPINE
Although spine radiosurgery is a well-developed extracranial
application of SRS and SBRT, and considerable efficacy and safety
data have been published, there is limited data on the cost-
effectiveness of the procedure (Table 2). In comparing external
beam radiation therapy (EBRT) to SBRT for spinal metastases,
Haley et al. (2011) found that the total cost to treat 100 patients
with SBRT (including a 9% retreatment rate) was $842,420, while
the cost to treat 30 Gy in 10 fractions (including a 23% retreatment
rate) was $676,309 and the cost to treat 20 Gy in 5 fractions (includ-
ing a 23% retreatment rate) was $499,911. As noted, although
SBRT was more costly than EBRT, patients treated with EBRT had
higher levels of acute toxicities and were more likely to require
additional interventions at the treated sites. Papatheofanis et al.
(2009) constructed a Markov model to simulate outcomes of
patients undergoing non-chemotherapeutic interventions – either
CyberKnife SRS or EBRT – for metastatic spinal tumors. Patients
treated with CyberKnife SRS gained an additional net health ben-
efit of 0.08 QALY while the CyberKnife SRS cost was $11,812 and
EBRT was $13,745, a difference of $1,933.
The main limitations of these studies were the lack of head-
to-head comparative clinical and health economic data across
therapy options and the fact that side effect treatments varied
across patients.
Future trials should capture clinical and health economic data
as well as quality of life indicators across all treatment options.
The studies reviewed clearly demonstrate that SRS and SBRT
provide clinicians with an additional cost-effective treatment
option for spinal metastases that has better short-term results and
comparable long-term results to EBRT.
LUNG
While surgical resection is the standard of care for many patients
with non-small cell lung cancer (NSCLC), the location of the
tumor and age and health status of patients with lung cancer
often dictate whether they can undergo surgery. For those patients
who are not surgical candidates, conventional RT and, more
recently, SBRT, are treatment options. For many elderly patients
with comorbid conditions such as emphysema and COPD, breath
holding or controlled breathing (which may be required for RT
delivered without tumor motion management capabilities) fur-
ther reduces their options (Table 3). Lanni et al. (2011) compared
the clinical and cost outcomes of SBRT, 3-dimensional conformal
RT (3DCRT), and intensity modulated radiation therapy (IMRT)
for the treatment of medically inoperable NSCLC. The treatment
cost, calculated using the charge cost from the institution for the
technical and professional components, for 35 fractions of 3DCRT
was $55,705, $136,570 for 35 fractions of IMRT, and $52,471 for 4
fractions of SBRT. The actual cost for a 35-fraction 3DCRT ranged
from $50,000 to $61,000, while the actual cost of a 4-fraction SBRT
ranged from $41,000 to $57,000. At a median potential follow-up
of up to 36 months, SBRT had higher overall survival compared
to 3DCRT (71 vs. 42%). Sher et al. (2011) developed a Markov
model comparing SBRT, 3DCRT, and radiofrequency ablation
(RFA) for 65-year-old men with medically inoperable NSCLC.
In the base-case analysis, RFA, 3DCRT, and SBRT had a mean
cost per QALY of $44,648/1.45, $48,842/1.53, and $51,133/1.91, Ta
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respectively. The ICER for SBRT over 3DCRT was $6,000/QALY
and $14,100/QALY for SBRT over RFA. Compared to RFA and
3DCRT, SBRT had lower 3-year local recurrence, regional recur-
rence, and distant metastases rates. Puri et al. (2012) compared the
cost-effectiveness of surgical intervention and SBRT in high-risk
patients with stage I NSCLC. The median survival with surgery
was 4.1 years, and the 4-year survival was 51.4%. With SBRT, the
median survival was 2.9 years, and the 4-year survival was 30.1%.
The cause-specific survival was identical between the two groups,
and the difference in overall survival was not statistically signifi-
cant. Nevertheless, SBRT was estimated to have a mean expected
survival of 2.94 years at a cost of $14,153 and mean expected sur-
vival with surgery was 3.39 years at a cost of $17,629, for an ICER
of $7,753.
Limitations across these studies included the fact that the cost
analysis was modeled from a Payer’s perspective, rather than a
societal or combined perspective. In addition, since these stud-
ies were retrospective, survival benefits may not have been fully
captured across all therapy options. Ongoing cost-effectiveness
studies should be done prospectively and not only capture the
clinical outcomes of the different treatment options, but also
quality of life measures. Given the positive clinical and health
economic outcomes, SBRT provides a cost-effective and clini-
cally effective outpatient and non-invasive therapy option for
patients with NSCLC compared to conventional RT and RFA,
while surgery remains the first treatment option in terms of
cost-effectiveness.
PROSTATE
There are many different treatment options available to men diag-
nosed with localized prostate cancer including a variety of radia-
tion therapies – 3DCRT, IMRT, proton therapy, SBRT, brachyther-
apy (HDR and LDR) – as well as surgical options – open, laparo-
scopic, and robotic (Table 4). Using a Markov model, Parthan
et al. (2012) compared the cost-effectiveness of SBRT, IMRT, and
proton therapy. The work-time lost due to treatment for SBRT,
IMRT, and proton therapy was 10, 90, and 100 h, respectively.
From a payer perspective, SBRT dominated both IMRT and pro-
ton therapy (SBRT: cost $24,873; QALY 8.11; IMRT: cost $33,068;
QALY 8.05; proton therapy: cost $69,094; QALY 8.06). From a soci-
etal perspective, SBRT dominated both IMRT and proton therapy
(SBRT: cost $25,097; QALY 8.11; IMRT: cost $35,088; QALY 8.05;
proton therapy: cost $71,339; QALY 8.06). Hodges et al. (2012)
also utilized a Markov model to compare the cost-effectiveness
of SBRT and IMRT. The model assumed IMRT costs of $29,530
and SBRT costs of $14,315. Results showed that the mean cost
and QALYs for SBRT and IMRT were $22,152 and 7.9 years and
$35,431 and 7.9 years, respectively.
Some of the limitations of these two studies include the limited
long-term SBRT data for localized prostate cancer, thus poten-
tially causing the current study models to inaccurately estimate
SBRT clinical values. Future studies should focus not only on acute
and late toxicity and long-term (5+ year) biochemical disease-
free survival, but also focus on including cost and quality of life
measures.
Collectively, these studies demonstrated that SBRT is a cost
saving treatment option for localized prostate cancer. Ta
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PANCREAS
Recent studies, including the Eastern Cooperative Oncology
Group study E4201, demonstrated improved survival when
chemotherapy is combined with RT for patients with pancre-
atic cancer (Table 4). Murphy et al. (2012) compared the cost-
effectiveness of four different therapies – gemcitabine, gemcitabine
plus conventional RT, gemcitabine plus IMRT, and gemcitabine
plus SBRT. The base-case cost of gemcitabine alone, gemcitabine
plus SBRT, gemcitabine plus RT, and gemcitabine plus IMRT was
$42,900, $56,700, $59,900, and $69,500, respectively. Overall, SBRT
increased life expectancy by 0.20 QALY at an increased cost of
$13,700 compared with gemcitabine alone (ICER= $69,500 per
QALY). In the base-case analysis, gemcitabine plus SBRT domi-
nated the more costly and less effective options of gemcitabine plus
RT and gemcitabine plus IMRT. The study concluded that IMRT
exceeds what society considers cost-effective in the treatment of
locally advanced pancreatic cancer.
A limitation of this study was that the Markov model was used
to compare preliminary results from phase 3 clinical trials (gem-
citabine and gemcitabine plus RT in E4201) with phase 2 clinical
data (gemcitabine plus SBRT). In addition, the model assumed
actual costs and quality of life outcomes about supportive care
for patients with pancreatic cancer. Future research needs should
continue to capture the clinical outcomes but also add quality
of life and cost measures. This will allow researchers to combine
the clinical and health economic results in future publications.
Based on the data reviewed, chemotherapy plus SBRT increased
life expectancy compared to gemcitabine alone at a cost potentially
acceptable by today’s standards.
CONCLUSION
In our review of the current state of the research, SRS and
SBRT have clearly demonstrated their clinical value and eco-
nomic sustainability, often in comparison to long-standing and
well-accepted treatment options. From a patient perspective, SRS
and SBRT provide a patient-friendly treatment option compared
to other treatment options such as conventional RT, especially
those who live in a rural setting or a great distance from treat-
ment centers. SRS and SBRT also offer a treatment option that is
non-invasive and can be completed in the outpatient setting, thus
potentially freeing up valuable inpatient hospital resources as well
as allowing patients to resume their normal daily activity as quickly
as possible. Both from payer and societal perspectives, the clinical
and cost-effectiveness of SRS and SBRT have been demonstrated
to reduce health system utilization (medication, retreatment, etc.)
and minimize indirect costs, thus saving payers additional finan-
cial resources, and reducing the strain on the workforce. In times of
increasing resource constraint cost-effective and cost saving tech-
niques could be crucial for healthcare systems in order to maintain
their sustainability in the long run. Identifying such techniques
will require continued coupling of robust clinical research with
economic data.
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